国际药品价格政策对我国专利药品谈判采购的启示

The Experience of International Medicine Pricing Policies and the Implication to China Patented Medicine Negotiation Policy

目的:借鉴国际经验,为完善我国专利药谈判采购政策提出建议。方法:关键人物访谈法和文献综述法。结果及建议:目前国际专利药定价方法主要分为基于卫生技术评估定价、外部参考定价、内部参考定价和基于成本定价等,也有的通过药品购买政策形成药品价格。我国专利药政策还需要进一步完善,专利药谈判采购政策可与我国医保政策紧密结合。外部参考定价较适合应用于目前的专利药谈判采购政策,药物经济学评价作为今后专利药品定价的发展方向。

Objective： China＇s new patented medicine policies could be improved with international drug pricing experience.Methods： Key person interviews and hterature review. Results and Suggestion： The curve, at pricing method for international patented drug included health technology assessment （HTA）, external reference pricing （ERP）, internal reference price and cost based pricing as well as some purchasing policies. China＇s patented medicine policies are supposed to be related to health insurance policy, which needed to be further improved. Currently, ERP could be applied to patented medicine negotiation policy, while HTA system should be established gradually in the future.